Literature DB >> 9931326

PTEN is inversely correlated with the cell survival factor Akt/PKB and is inactivated via multiple mechanismsin haematological malignancies.

P L Dahia1, R C Aguiar, J Alberta, J B Kum, S Caron, H Sill, D J Marsh, J Ritz, A Freedman, C Stiles, C Eng.   

Abstract

PTEN is a novel tumour suppressor gene that encodes a dual-specificity phosphatase with homology to adhesion molecules tensin and auxillin. It recently has been suggested that PTEN dephosphorylates phosphatidylinositol 3,4,5-trisphosphate [PtdIns(3, 4,5)P3], which mediates growth factor-induced activation of intracellular signalling, in particular through the serine-threonine kinase Akt, a known cell survival-promoting factor. PTEN has been mapped to 10q23.3, a region disrupted in several human tumours including haematological malignancies. We have analysed PTEN in a series of primary acute leukaemias and non-Hodgkin's lymphomas (NHLs) as well as in cell lines. We have also examined whether a correlation could be found between PTEN and Akt levels in these samples. We show here that the majority of cell lines studied carries PTEN abnormalities. At the structural level, we found mutations and hemizygous deletions in 40% of these cell lines, while a smaller number of primary haematological malignancies, in particular NHLs, carries PTEN mutations. Moreover, one-third of the cell lines had low PTEN transcript levels, and 60% of these samples had low or absent PTEN protein, which could not be attributed to gene silencing by hypermethylation. In addition, we found that PTEN and phosphorylated Akt levels are inversely correlated in the large majority of the examined samples. These findings suggest that PTEN plays a role in the pathogenesis of haematological malignancies and that it might be inactivated through a wider range of mechanisms than initially considered. The finding that PTEN levels inversely correlate with phosphorylated Akt supports the hypothesis that PTEN regulates PtdIns(3,4,5)P3and suggests a role for PTEN in apoptosis.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 9931326     DOI: 10.1093/hmg/8.2.185

Source DB:  PubMed          Journal:  Hum Mol Genet        ISSN: 0964-6906            Impact factor:   6.150


  69 in total

1.  Linking molecular therapeutics to molecular diagnostics: inhibition of the FRAP/RAFT/TOR component of the PI3K pathway preferentially blocks PTEN mutant cells in vitro and in vivo.

Authors:  G B Mills; Y Lu; E C Kohn
Journal:  Proc Natl Acad Sci U S A       Date:  2001-08-28       Impact factor: 11.205

2.  Epigenetic PTEN silencing in malignant melanomas without PTEN mutation.

Authors:  X P Zhou; O Gimm; H Hampel; T Niemann; M J Walker; C Eng
Journal:  Am J Pathol       Date:  2000-10       Impact factor: 4.307

3.  PTEN expression causes feedback upregulation of insulin receptor substrate 2.

Authors:  L Simpson; J Li; D Liaw; I Hennessy; J Oliner; F Christians; R Parsons
Journal:  Mol Cell Biol       Date:  2001-06       Impact factor: 4.272

4.  Critical role of PICT-1, a tumor suppressor candidate, in phosphatidylinositol 3,4,5-trisphosphate signals and tumorigenic transformation.

Authors:  Fumiaki Okahara; Kouichi Itoh; Akira Nakagawara; Makoto Murakami; Yasunori Kanaho; Tomohiko Maehama
Journal:  Mol Biol Cell       Date:  2006-09-13       Impact factor: 4.138

5.  Targeting the RAF/MEK/ERK, PI3K/AKT and p53 pathways in hematopoietic drug resistance.

Authors:  James A McCubrey; Linda S Steelman; Richard A Franklin; Steven L Abrams; William H Chappell; Ellis W T Wong; Brian D Lehmann; David M Terrian; Jorg Basecke; Franca Stivala; Massimo Libra; Camilla Evangelisti; Alberto M Martelli
Journal:  Adv Enzyme Regul       Date:  2007-03-26

6.  Therapeutic targeting of cancers with loss of PTEN function.

Authors:  Lloye M Dillon; Todd W Miller
Journal:  Curr Drug Targets       Date:  2014-01       Impact factor: 3.465

7.  Glioma is formed by active Akt1 alone and promoted by active Rac1 in transgenic zebrafish.

Authors:  In Hye Jung; Ga Lam Leem; Dawoon E Jung; Min Hee Kim; Eun Young Kim; Se Hoon Kim; Hae-Chul Park; Seung Woo Park
Journal:  Neuro Oncol       Date:  2013-01-16       Impact factor: 12.300

Review 8.  DNA damage response, redox status and hematopoiesis.

Authors:  Cary N Weiss; Keisuke Ito
Journal:  Blood Cells Mol Dis       Date:  2013-09-13       Impact factor: 3.039

9.  Enhanced apoptosis in pilocytic astrocytoma: a comparative study of apoptosis and proliferation in astrocytic tumors.

Authors:  Akira Nakamizo; Takanori Inamura; Kiyonobu Ikezaki; Koji Yoshimoto; Satoshi Inoha; Masahiro Mizoguchi; Toshiyuki Amano; Masashi Fukui
Journal:  J Neurooncol       Date:  2002-04       Impact factor: 4.130

10.  Utility of PTEN protein dosage in predicting for underlying germline PTEN mutations among patients presenting with thyroid cancer and Cowden-like phenotypes.

Authors:  Joanne Ngeow; Xin He; Jessica L Mester; Junying Lei; Todd Romigh; Mohammed S Orloff; Mira Milas; Charis Eng
Journal:  J Clin Endocrinol Metab       Date:  2012-10-12       Impact factor: 5.958

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.